Mirae Asset Global Investments Co. Ltd. Buys 6,495 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Mirae Asset Global Investments Co. Ltd. raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 21.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 36,579 shares of the medical equipment provider’s stock after buying an additional 6,495 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Zimmer Biomet were worth $3,289,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Brighton Jones LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at about $204,000. Sivia Capital Partners LLC acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at about $232,000. United Bank lifted its stake in shares of Zimmer Biomet by 10.7% in the 2nd quarter. United Bank now owns 11,896 shares of the medical equipment provider’s stock valued at $1,085,000 after purchasing an additional 1,153 shares during the period. Federated Hermes Inc. lifted its stake in shares of Zimmer Biomet by 129.2% in the 2nd quarter. Federated Hermes Inc. now owns 2,132 shares of the medical equipment provider’s stock valued at $194,000 after purchasing an additional 1,202 shares during the period. Finally, Cerity Partners LLC lifted its stake in shares of Zimmer Biomet by 93.6% in the 2nd quarter. Cerity Partners LLC now owns 76,785 shares of the medical equipment provider’s stock valued at $7,004,000 after purchasing an additional 37,116 shares during the period. Institutional investors own 88.89% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The stock was sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president directly owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Stock Up 0.4%

ZBH stock opened at $93.02 on Thursday. The stock’s 50 day simple moving average is $93.75 and its 200 day simple moving average is $93.15. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $84.59 and a fifty-two week high of $108.29. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The company has a market cap of $18.01 billion, a P/E ratio of 26.28, a price-to-earnings-growth ratio of 1.90 and a beta of 0.61.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The business had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. During the same period in the prior year, the business earned $2.31 EPS. The firm’s revenue for the quarter was up 10.9% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.39 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date of this dividend is Tuesday, March 31st. Zimmer Biomet’s dividend payout ratio is 27.12%.

Analyst Upgrades and Downgrades

ZBH has been the topic of a number of recent analyst reports. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their price objective for the company from $94.00 to $120.00 in a research note on Monday, January 5th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Tuesday, February 10th. UBS Group reissued a “sell” rating and issued a $89.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, February 11th. William Blair initiated coverage on Zimmer Biomet in a research note on Friday, February 20th. They issued a “market perform” rating on the stock. Finally, Wall Street Zen downgraded Zimmer Biomet from a “buy” rating to a “hold” rating in a research note on Sunday. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $105.95.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.